Perry Andrew's Insider Trades & SAST Disclosures
Perry Andrew's most recent trade in G1 Therapeutics Inc was a trade of 114,482 Common Stock done . Disclosure was reported to the exchange on Sept. 18, 2024.
Add Superstar Alert
Share
Note
This is a custom search result for pattern Perry Andrew.To see full superstar portfolios of large investors like Warren Buffet, Elon Musk and others, click here.
Advanced/Help
"Balanced Fund": Use this format with quotation marks to find the exact phrase. The output matches
"Balanced Fund"
but not "Balanced Growth Fund"
Balanced Fund: Use this format without quotation marks to search for all funds related to the term
"Balanced Fund" The results may include
"Balanced Income Fund", "Balanced Growth Fund" and any fund name containing "Balanced Fund".
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| G1 Therapeutics Inc | Andrew Perry | Chief Commercial Officer | Sale or transfer of securities back to the company at price $ 0.00 per share. | 18 Sep 2024 | 114,482 | 14,232 (0%) | 0% | - | Common Stock | |
| G1 Therapeutics Inc | Andrew Perry | Chief Commercial Officer | Sale or transfer of securities back to the company at price $ 0.00 per share. | 18 Sep 2024 | 67,050 | 0 | - | - | Stock Option (right to buy) | |
| G1 Therapeutics Inc | Andrew Perry | Chief Commercial Officer | Sale or transfer of securities back to the company at price $ 0.00 per share. | 18 Sep 2024 | 32,100 | 0 | - | - | Stock Option (right to buy) | |
| G1 Therapeutics Inc | Andrew Perry | Chief Commercial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 Sep 2024 | 16,100 | 128,714 (0%) | 0% | - | Common Stock | |
| G1 Therapeutics Inc | Andrew Perry | Chief Commercial Officer | 18 Sep 2024 | 14,232 | 0 (0%) | 0% | - | Common Stock | ||
| G1 Therapeutics Inc | Andrew Perry | Chief Commercial Officer | Sale of securities on an exchange or to another person at price $ 2.51 per share. | 05 Jul 2024 | 1,337 | 112,614 (0%) | 0% | 2.5 | 3,353 | Common Stock |
| G1 Therapeutics Inc | Andrew Perry | Chief Commercial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Jul 2024 | 35,000 | 113,951 (0%) | 0% | 0 | Common Stock | |
| G1 Therapeutics Inc | Andrew Perry | Chief Commercial Officer | Sale of securities on an exchange or to another person at price $ 4.79 per share. | 13 May 2024 | 8,151 | 78,951 (0%) | 0% | 4.8 | 39,034 | Common Stock |
| G1 Therapeutics Inc | Perry Andrew | Chief Commercial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Jan 2024 | 67,050 | 67,050 | - | - | Stock Options (Right to Buy) | |
| G1 Therapeutics Inc | Andrew Perry | Chief Commercial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Jan 2024 | 33,570 | 89,515 (0%) | 0% | 0 | Common Stock | |
| G1 Therapeutics Inc | Andrew Perry | Chief Commercial Officer | Sale of securities on an exchange or to another person at price $ 3.12 per share. | 03 Jan 2024 | 2,034 | 87,102 (0%) | 0% | 3.1 | 6,344 | Common Stock |
| G1 Therapeutics Inc | Perry Andrew | Chief Commercial Officer | Sale of securities on an exchange or to another person at price $ 3.12 per share. | 03 Jan 2024 | 379 | 89,136 (0%) | 0% | 3.1 | 1,182 | Common Stock |
| G1 Therapeutics Inc | Andrew Perry | Chief Commercial Officer | Sale of securities on an exchange or to another person at price $ 2.45 per share. | 05 Jul 2023 | 355 | 55,945 (0%) | 0% | 2.5 | 871 | Common Stock |
| G1 Therapeutics Inc | Andrew Perry | Chief Commercial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 May 2023 | 35,000 | 56,300 (0%) | 0% | 0 | Common Stock | |
| G1 Therapeutics Inc | Andrew Perry | Chief Commercial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Jan 2023 | 32,100 | 32,100 | - | - | Stock Options (Right to buy) | |
| G1 Therapeutics Inc | Andrew Perry | Chief Commercial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Jan 2023 | 16,100 | 22,120 (0%) | 0% | 0 | Common Stock | |
| G1 Therapeutics Inc | Andrew Perry | Chief Commercial Officer | Sale of securities on an exchange or to another person at price $ 5.58 per share. | 03 Jan 2023 | 820 | 21,300 (0%) | 0% | 5.6 | 4,572 | Common Stock |
| G1 Therapeutics Inc | Andrew Perry | Chief Commercial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Jan 2022 | 26,500 | 26,500 | - | - | Stock Options (Right to buy) | |
| G1 Therapeutics Inc | Andrew Perry | Chief Commercial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Jan 2022 | 6,000 | 6,020 (0%) | 0% | 0 | Common Stock | |
| G1 Therapeutics Inc | Andrew Perry | Chief Commercial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Aug 2021 | 300,000 | 300,000 | - | - | Stock Options (Right to buy) |
*All Values are in $ Million
Client Category: Promoter/ KMP/ Director / Immediate Relatives / Employee / etc
Security Type: Share/ Warrants / Convertible Debentures
Security Type: Share/ Warrants / Convertible Debentures
Data as reported to USA Exchanges